Press Releases

Perrigo Company plc (NYSE; TASE: PRGO) today announced it has received tentative approval from the U.S. Food and Drug Administration for the generic version of Onexton® Gel (clindamycin phosphate...

Perrigo Company plc (NYSE; TASE: PRGO) today announced it has received final approval from the U.S. Food and Drug Administration for the generic version of Estrace® Cream (estradiol vaginal...

Perrigo Company plc (NYSE; TASE: PRGO) today announced it has received final approval from the U.S. Food and Drug Administration and has launched an AB rated generic version of Epiduo® (adapalene...

Perrigo Company plc (NYSE; TASE: PRGO), a leading global provider of Quality Affordable Healthcare Products®, today announced the appointment of Uwe Röhrhoff as Chief Executive Officer,...

Perrigo Company plc (NYSE; TASE: PRGO) today announced it has received tentative approval from the U.S. Food and Drug Administration for the generic version of Prolensa® (bromfenac ophthalmic...

Perrigo Company plc (NYSE: PRGO; TASE) today announced that John T. Hendrickson, Perrigo Chief Executive Officer, will present at the 36th Annual J.P. Morgan Healthcare Conference at 12:00 PM EST...

Perrigo Company plc (NYSE; TASE: PRGO) today announced the launch of an AB rated generic version of Mycolog® II Cream (nystatin and triamcinolone acetonide cream USP, 100,000 units/gram and 1...

Perrigo Company plc (NYSE; TASE: PRGO) today announced the launch of an AB rated generic version of Exalgo® 32mg extended release tablets (hydromorphone HCl) C-II. Exalgo® 32mg extended release...

Perrigo Company plc (NYSE: PRGO; TASE) today announced that it has completed the previously announced divestiture of its Active Pharmaceutical Ingredient (API) business based in Israel to SK...

Perrigo Company plc (NYSE: PRGO; TASE) today announced that John T. Hendrickson, Perrigo Chief Executive Officer, will present at the 2017 Stifel Healthcare Conference at 8:45 AM EST on Tuesday,...

Delivered third quarter 2017 GAAP ("reported") net sales of $1.2 billion, reported net income of $45 million and reported diluted earnings per share ("EPS") of $0.31 compared to a loss per share...

Perrigo Company plc (NYSE; TASE: PRGO) today announced that its Board of Directors declared a quarterly dividend of $0.16 per share, payable on December 19, 2017 to shareholders of record on...

Perrigo Company plc (NYSE; TASE: PRGO) today announced it has received tentative approval from the U.S. Food and Drug Administration ("FDA") for the generic version of Picato® Gel (ingenol...

Perrigo Company plc (NYSE; TASE: PRGO) today announced that it will release its third quarter 2017 financial results on Thursday, November 9, 2017. The Company will also host a conference call...

Perrigo Company plc (NYSE; TASE: PRGO) today announced that it has settled the Hatch-Waxman litigation relating to Onexton® Gel (clindamycin phosphate 1.2% and benzoyl peroxide 3.75%) brought by...

Perrigo Company plc (NYSE; TASE: PRGO) today announced it has received tentative approval from the U.S. Food and Drug Administration ("FDA") for the generic version of Picato® Gel (ingenol...

Perrigo Company plc (NYSE; TASE: PRGO) today announced it has initiated shipments to retail customers of the first-to-market over-the-counter ("OTC") store brand equivalent of Nexium® 24HR...

Perrigo Company plc (NYSE; TASE: PRGO) today announced it has received final approval from the U.S. Food and Drug Administration for its AB rated Abbreviated New Drug Application referencing...

Perrigo Company plc (NYSE; TASE: PRGO) today announced it has received tentative approval from the U.S. Food and Drug Administration for the generic version of Acanya® (clindamycin phosphate and...

Perrigo Company plc (NYSE: PRGO; TASE) today announced that John T. Hendrickson, Perrigo Chief Executive Officer, will present at the 2017 Wells Fargo Healthcare Conference at 4:10 PM EDT on...

Perrigo Company plc (NYSE; TASE: PRGO) today announced that it has received final approval from the U.S. Food & Drug Administration for the store brand OTC equivalent of Nexium® 24HR...

Perrigo Company plc (NYSE; TASE: PRGO) today announced it has received final approval from the U.S. Food and Drug Administration for its AB rated Abbreviated New Drug Application referencing...

Delivered second quarter 2017 GAAP ("reported") net sales of $1.2 billion CHC Americas segment reported nets sales of $605 million compared to $630 million last year, lower by 4%; Adjusted net...

Perrigo Company plc (NYSE; TASE: PRGO) today announced that its Board of Directors declared a quarterly dividend of $0.16 per share, payable on September 12, 2017 to shareholders of record on...

Perrigo Company plc (NYSE; TASE: PRGO) today announced it has received tentative approval from the U.S. Food and Drug Administration for the generic version of Mirvaso® (brimonidine) topical gel...

Perrigo Company plc (NYSE; TASE: PRGO) and its co-development partner Aveva Drug Delivery Systems, Inc., an Apotex Company, today announced the prescription pharmaceutical launch of scopolamine...

Perrigo Company plc (NYSE; TASE: PRGO) today announced that it will release its second quarter 2017 financial results on Thursday, August 10, 2017. The Company will conduct a conference call at...

Perrigo Company plc (NYSE; TASE: PRGO) today announced it has received final approval from the U.S. Food and Drug Administration for its AB rated Abbreviated New Drug Application referencing...

Perrigo Company plc (NYSE: PRGO; TASE) today announced that its subsidiary has filed a Paragraph IV Abbreviated New Drug Application with the U.S. Food and Drug Administration for a generic...

Perrigo Company plc (NYSE; TASE: PRGO) today announced it has received final approval from the U.S. Food and Drug Administration for its AB rated Abbreviated New Drug Application referencing...

Perrigo Company plc (NYSE; TASE: PRGO) today announced that it has settled the Hatch-Waxman litigation relating to Dymista® (azelastine hydrochloride and fluticasone propionate) nasal spray...

Perrigo Company plc (NYSE; TASE: PRGO) today announced the prescription pharmaceutical launch of testosterone topical solution, 30 mg/1.5 mL (CIII), the generic equivalent to Eli Lilly and...

Perrigo Company plc (NYSE; TASE: PRGO), a leading global provider of "Quality Affordable Healthcare Products®", today announced that the Company's Board of Directors has retained Spencer Stuart,...

Perrigo Company plc (NYSE; TASE: PRGO) today announced it has launched its generic equivalents to Hill Laboratories Inc.'s Derma-Smoothe/FS® Scalp Oil (fluocinolone acetonide scalp oil, 0.01%)...

Perrigo Company plc (NYSE; TASE: PRGO) today announced it has launched hydrocodone bitartrate and homatropine methylbromide oral solution. Hydrocodone bitartrate and homatropine methylbromide oral...

Perrigo Company plc ("Perrigo" or the "Company") (NYSE; TASE: PRGO) announced today the reference yield and total consideration for each series of notes subject to the previously announced cash...

Perrigo Company plc (NYSE: PRGO; TASE) today announced that Jeff Needham, Perrigo's Executive Vice President and President, Consumer Healthcare Americas, will present at the Oppenheimer 2017...

Perrigo Company plc ("Perrigo" or the "Company") (NYSE; TASE: PRGO) announced today the early tender results as of 5:00 p.m., New York City time, June 13, 2017 (the "Early Tender Deadline") for...

Perrigo Company plc (NYSE; TASE: PRGO), a leading global provider of Quality Affordable Healthcare Products®, today announced the forthcoming retirement of Chief Executive Officer John T....

Perrigo Company plc (NYSE: PRGO; TASE) today announced that Perrigo CEO John T. Hendrickson will present at the Jefferies 2017 Healthcare Conference at 3:00 PM EDT on Tuesday, June 6, 2017....

Perrigo Company plc ("Perrigo" or the "Company") (NYSE; TASE: PRGO) announced today that it and Perrigo Finance Unlimited Company, its wholly-owned finance subsidiary ("Perrigo Finance"), have...

Perrigo Company plc (NYSE; TASE: PRGO) today announced that it will conduct a conference call on Wednesday, May 31 at 8:30AM (ET) hosted by John T. Hendrickson, Perrigo's Chief Executive Officer,...

Delivered first quarter 2017 GAAP ("reported") net sales of $1.2 billion, led by consumer-facing businesses net sales of $958 million Realized first quarter reported net income of $72 million and...

Perrigo Company plc (NYSE; TASE: PRGO) today announced that it will conduct a conference call on Tuesday, May 23 at 8:30AM (ET) hosted by John T. Hendrickson, Perrigo's Chief Executive Officer, to...

Comprehensive Form 10-K reflects accounting treatment of historical Tysabri® royalty stream as a financial asset No impact on net cash flows or previously closed sale of Tysabri® Revised...

Perrigo Company plc (NYSE; TASE: PRGO) today announced the appointment of Rolf A. Classon and Adriana Karaboutis to the Company's Board of Directors. Pursuant to the agreement with Starboard Value...

Perrigo Company plc (NYSE, TASE: PRGO) today announced that its Board of Directors declared a quarterly dividend of $0.16 per share, payable on June 13, 2017 to shareholders of record on May 26, 2017.

Perrigo Company plc (NYSE; TASE: PRGO) today announced that search warrants were executed at the Company's corporate offices associated with an ongoing investigation by the U.S. Department of...

Perrigo Company plc (NYSE; TASE: PRGO), a leading provider of Quality, Affordable Healthcare Products®, today announced that the Company's Board of Directors, after consultation with management...

Perrigo Company plc (NYSE; TASE: PRGO), a leading global provider of Quality Affordable Healthcare Products®, today announced it has completed the divestiture of its rights to the royalty stream...